Articles

Treasury bonds are good investments at this time of year — but not because of the Fed

Prices peak in the late fall and bottom in the spring.

As bubble debate rages, a new study finds why companies are getting stuck by the AI productivity paradox

Companies do benefit from attracting AI workers, but only from lean organizations, study finds

15 stocks of S&P 500 companies growing sales the most while improving profit margins

These companies combine high sales growth with improving productivity and efficiency.

Social Security survivor benefits from my late husband are not enough. Can I claim more on his record?

“My ex-husband passed away four years ago. We were married for 20 years.”

Novo Nordisk downgrades sales outlook again amid bidding war with Pfizer for Metsera

Management lowers full-year guidance, warns about competition, launches bid for Metsera.

I invested $200K in my daughter’s 529 plan. She doesn’t want to go to college. What should I do with this money?

“Are there any other ways I can consider transferring the wealth to her?”

‘It’s survival math every month’: The rent crisis that got Zohran Mamdani elected goes far beyond New York City

The mayor-elect built his campaign around rent affordability. But the same issue applies across the country, according to experts — and the many people struggling to pay their rent each month.

Why Super Micro’s stock is falling after earnings — even as guidance moves higher

Super Micro continued to exhibit margin pressure in the latest quarter, reflecting a competitive server market.

As speculative corners of the market tumble, some investors are cheering

“What is being brought down are the things that are were too speculative in nature,” says Morgan Stanley’s Andrew Slimmon

Upstart’s stock extends declines as the AI lender predicts slower growth

Upstart’s December-quarter revenue is expected to slow more than Wall Street had been modeling.

Strategy’s stock falls to 7-month low. Why the leveraged bitcoin play is losing steam.

Shares of Strategy ended at their lowest level in seven months, a sign that investors may be growing cautious about Saylor’s highly leveraged bitcoin-buying playbook.

Medicare recipients may get obesity drugs for just $149 a month under a reported White House deal in the works

The White House is close to announcing a deal with drugmakers Eli Lilly and Novo Nordisk that would cut the price of obesity drugs to $149 per month in some cases and extend coverage to certain Medicare and Medicaid beneficiaries, according to media reports Tuesday.
1 33 34 35 36 37 2,441